Gilead Sciences Inc (GILD) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Total Revenue Chart for Gilead Sciences Inc

Gilead Sciences Inc (GILD) revenue for FY2025 was USD 29.4B, a 2.4% change from FY2024. Gilead Sciences Inc's revenue grew from USD 1.3M in 1990 to USD 29.4B in 2025 (2264669.2% over 35 years). Earnings per share grew from USD 0.03 in 2001 to USD 3.64 in 2022 (11406.8%). Revenue compound annual growth rate: 5-year CAGR of 3.6%, 10-year CAGR of -1.0%, 20-year CAGR of 14.3%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.